Objectives Presence of Psoriatic Arthritis (PsA) in patients with Psoriasis (PsO) imposes
significant disease burden and poor quality of life, demonstrating the need for multi-faceted …

Objectives Assess the prevalence of comorbidities among PsO patients with PsA (PsO+
PsA) and without PsA (PsO-alone) treated with biologics in UK/Germany/France/Italy/Spain …

Background Psoriasis (PsO) and Psoriatic Arthritis (PsA) imposes significant burden among
patients with these disease conditions. Patients with both of these conditions may …

Background Limited research has been conducted on whether advances in novel biologics
and biosimilars have improved the treatment journey preceding biologics. Objectives To …

Background Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved
significantly since the era of biologics. Clinical trials (mainly placebo-controlled for 12 to 16 …

Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis that can lead to
decreased health-related quality of life and permanent joint damage leading to functional …

Background Real-world data can inform the use of biologics for psoriasis (PSO). Objective
The aim was to evaluate treatment patterns and analyze pharmacoutilization in PSO patients …

Psoriatic arthritis (PsA) is well known to affect the skin and joints and emerging research has
identified specific comorbidities related to PsA. More than half of patients with PsA have at …

Background Up to 40% of patients with psoriasis (PsO) develop psoriatic arthritis (PsA),
which can have a significant impact on health-related quality of life (HRQoL)[1]. Among …

Importance Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved
significantly throughout the era of biologics. Clinical trials are inadequate to assess the …